Physician profile
Eric John Reed
NPI 1538555123
$3,007.13
in general payments reported to CMS, 2019-2025
15 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.23 · 2022: $342 · 2023: $731 · 2024: $731 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,616.19 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $971.25 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $446.70 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $307.00 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $251.15 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $225.11 | 2022-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $160.29 | 2025 | Cobenfy |
| Alkermes, INC. | $142.53 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $112.33 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $105.18 | 2024-2025 | Ingrezza |
| Indivior INC. | $95.55 | 2022-2025 | Sublocade |
| Sage Therapeutics, LLC | $63.98 | 2024-2025 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $58.79 | 2024-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $28.85 | 2024 | Sunosi |
| Corium, LLC | $19.35 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.